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Abstract: As the spread of antibiotic resistant bacteria steadily increases, there is an urgent 
need for new antibacterial agents. Because fatty acid synthesis is only used for membrane 
biogenesis in bacteria, the enzymes in this pathway are attractive targets for antibacterial 
agent development. Acetyl-CoA carboxylase catalyzes the committed and regulated step in 
fatty acid synthesis. In bacteria, the enzyme is composed of three distinct protein 
components: biotin carboxylase, biotin carboxyl carrier protein, and carboxyltransferase. 
Fragment-based screening revealed that amino-oxazole inhibits biotin carboxylase activity 
and also exhibits antibacterial activity against Gram-negative organisms. In this report, we 
redesigned previously identified lead inhibitors to expand the spectrum of bacteria 
sensitive to the amino-oxazole derivatives by including Gram-positive species. Using 9,411 
small organic building blocks, we constructed a diverse combinatorial library of 1.2 × 108 
amino-oxazole derivatives. A subset of 9 × 106 of these compounds were subjected to 
structure-based virtual screening against seven biotin carboxylase isoforms using 
similarity-based docking by eSimDock. Potentially broad-spectrum antibiotic candidates 
were selected based on the consensus ranking by several scoring functions including non-
linear statistical models implemented in eSimDock and traditional molecular mechanics 
force fields. The analysis of binding poses of the top-ranked compounds docked to biotin 
carboxylase isoforms suggests that: (1) binding of the amino-oxazole anchor is stabilized 
by a network of hydrogen bonds to residues 201, 202 and 204; (2) halogenated aromatic 
moieties attached to the amino-oxazole scaffold enhance interactions with a hydrophobic 
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pocket formed by residues 157, 169, 171 and 203; and (3) larger substituents reach deeper 
into the binding pocket to form additional hydrogen bonds with the side chains of residues 
209 and 233. These structural insights into drug-biotin carboxylase interactions will be 
tested experimentally in in vitro and in vivo systems to increase the potency of amino-
oxazole inhibitors towards both Gram-negative as well as Gram-positive species. 
Keywords: biotin carboxylase; acetyl-CoA carboxylase; biotin carboxylase inhibitors; 




The dramatic increase in the number of pathogenic bacteria with extensive resistance to antibiotics 
has been well documented in both the scientific literature [1,2] and popular media. For instance, 
resistance is particularly problematic in the Gram-positive organism Staphylococcus aureus (e.g., 
methicillin resistant Staphylococcus aureus-MRSA) as well as a number of Gram-negative organisms 
like Klebsiella pneumonia, Acinetobacter baumannii, and Pseudomonas aeruginosa [3]. In order to 
mitigate this problem, new antibiotics directed against new target molecules are desperately needed. 
Since fatty acids are only used for membrane biogenesis in bacteria, the enzymes of the fatty acid 
biosynthetic pathway are potential targets for the development of novel antibacterial agents [4–6]. 
The rate-determining and committed reaction in fatty acid biosynthesis in bacteria is catalyzed by 
acetyl-CoA carboxylase [7]. Acetyl-CoA carboxylase (ACC) is a multifunctional enzyme that 
catalyzes the two-step reaction shown in Scheme 1 [8]. In the first half-reaction, biotin carboxylase 
(BC) catalyzes the ATP-dependent carboxylation of the vitamin biotin, which in vivo is covalently 
attached to the biotin carboxyl carrier protein (BCCP). In the second half-reaction, carboxyltransferase 
catalyzes the transfer of the carboxyl group from biotin to acetyl-CoA to form malonyl-CoA, which is 
the substrate for fatty acid synthase. In Gram-positive and Gram-negative bacteria, BC, BCCP and 
carboxyltransferase are separate proteins that form a complex in vivo [9]. However, when either BC or 
carboxyltransferase are purified, they retain their enzymatic activity in the absence of the other two 
components. Most importantly, both BC [10] and carboxyltransferase [11] have been validated as 
targets for antibacterial development. 
Three different classes of molecules have been found to inhibit bacterial BC and also  
exhibit antibacterial activity: pyridopyrimidines [10], amino-oxazoles [12] and the benzimidazole 
carboxamides [13]. Scientists at Pfizer were the first to discover an antibiotic targeting BC [10]. Whole 
cell screening of a 1.6 × 106 compound library revealed that pyridopyrimidines had potent antibacterial 
activity. When strains of H. influenzae resistant to the pyridopyrimidines were generated, the resistant 
mutation mapped to the gene coding for BC. The pyridopyrimidines inhibited BC with a Ki of 0.8 nM 
by competing with ATP for binding to the enzyme. Surprisingly, and fortunately, the pyridopyrimidines 
did not inhibit human acetyl-CoA carboxylase. However, the pyridopyrimidines were only effective 
against Gram-negative organisms such as E. coli, H. influenzae and M. catarrhalis, and showed limited 
antibacterial activity against Gram-positive organisms. 
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Scheme 1. Reaction mechanism of bacterial acetyl-CoA carboxylase. 
 
Using the three-dimensional structure of BC bound to pyridopyrimidines as a starting point, the 
Pfizer group then applied a combination of virtual screening and fragment based drug design to 
discover a series of low molecular weight inhibitors of BC [12,14]. The advantage of these low 
molecular weight inhibitors versus the pyridopyrimidines is that they were more amenable to synthetic 
elaboration. One of these inhibitors, 2-amino-oxazole (Figure 1a), was subjected to fragment growing 
to generate the dibenzylamide analog shown in Figure 1b. Like the pyridopyrimidines, the 
dibenzylamide analog inhibited bacterial BC by binding in the ATP binding site, but did not inhibit the 
human enzyme. Also, like the pyridopyrimidines, amino-oxazole dibenzylamide showed strong 
antibacterial activity against Gram-negative organisms, while exhibiting limited activity against Gram-
positive organisms. Thus, the major shortcoming of both the pyridopyrimidines and the amino-oxazole 
derivatives as antibiotics is that they had a very narrow spectrum of activity, i.e., they were only 
effective against Gram-negative bacteria. Since the pyridopyrimidines are not synthetically tractable, 
the best chance for developing a broad-spectrum antibacterial agent that targets BC is to focus on the 
amino-oxazole scaffold. While the amino-oxazole fragment (Figure 1a) can serve as an anchor to bind 
in the ATP binding site, the carboxyl group provides a very accessible functionality that can be easily 
modified with a variety of nitrogen containing ligands using standard peptide coupling conditions. This 
was the synthetic approach used by the Pfizer group in their initial studies of amino-oxazole 
derivatives [12,14]. Therefore, a fragment could be attached to amino-oxazole that renders the 
molecule able to bind to BC from both Gram-negative and Gram-positive bacteria would have the 
potential to exhibit broad-spectrum activity. Thus, the purpose of this study is to identify low 
molecular weight fragments that could be coupled to the amino-oxazole scaffold and enable the 
molecule to bind to BC from both Gram-negative and Gram-positive bacteria. The major hurdle is how 
to identify low molecular weight fragments that can bind to BC from both Gram-negative and  
Gram-positive bacteria. 
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Figure 1. Low molecular weight inhibitors of biotin carboxylase. (a) 2-Amino-oxazole,  
(b) dibenzylamide analog. 
 
Computer-based approaches are routinely used in modern drug discovery to significantly  
reduce time and costs associated with the development of new biopharmaceuticals. Many  
experimental techniques, such as high-throughput screening and combinatorial chemistry, involve 
relatively random processes, thus the overall efficiency of the discovery process can be greatly 
improved by using computer technologies to design more focused experiments [15]. Amongst many 
computational methods, structure-based virtual screening is one of the most widely used to support 
drug development [16,17]. These algorithms extensively use structural information available for target 
proteins to limit the size of chemical libraries to those compounds that are most likely to exhibit the 
desired bioactivities. In virtual screening by molecular docking, each drug candidate is docked into the 
protein target using a conformational search algorithm and a scoring function, which is followed by 
affinity prediction from drug-target interactions modeled at the molecular level. Considering the 
constantly increasing throughput capabilities of high-performance computing systems, structure-based 
virtual screening can be applied to systematically evaluate a large number of small organic compounds 
prior to experimental testing [18]. On that account, these techniques are particularly powerful in 
investigating diverse combinatorial libraries, whose considerable size in the order of millions of 
molecules surpasses the capacity of experimental high-throughput screening. Examples of  
structure-based virtual screening include the successful development of anti-influenza agents [19], the 
discovery of novel compounds with anti-herpes activity [20], and the discovery of a novel high-affinity 
ligand for human carbonic anhydrase II [21]. 
In this study, we first constructed a large combinatorial library of antibiotic candidates containing 
the amino-oxazole scaffold. These compounds were subsequently subjected to structure-based virtual 
screening against several BC isoforms from both Gram-positive and Gram-negative species. Binding 
poses of potentially broad-spectrum inhibitors selected from docking simulations were analyzed in 
order to shed light onto the possible structural determinants responsible for the high antibiotic potency 
of amino-oxazoles towards bacterial BC. 
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2. Results and Discussion 
The flowchart shown in Figure 2 illustrates the modeling procedure used to redesign amino-oxazole 
inhibitors of BC. Specifically, our goal is to find chemical moieties which, when attached at positions 
R1 and R2 of the amino-oxazole scaffold (Figure 2a), would result in an increased potency of this class 
of BC inhibitors against both Gram-negative and Gram-positive bacteria species.  
Figure 2. Flowchart of the computational redesign of biotin carboxylase inhibitors. 
Amino-oxazole scaffold (a) is used to anchor different chemical moieties (b) at positions 
R1 and R2 in order to construct a large combinatorial library of amino-oxazole derivatives 
(c). For a subset of compounds (d), 3D conformations (e) and conformational ensembles 
(f) are generated. These are systematically docked to biotin carboxylase isoforms from 
seven bacterial species (g) using eSimDock (h). Initial binding poses are subject to all-
atom refinement using AMMOS (i). The final binding poses are scored, ranked and 
analyzed (j). 
 
Using a library of small organic building blocks (Figure 2b) and virtual combinatorial chemistry 
techniques, we systematically explored all possible combinations of small fragments attached at 
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positions R1 and R2 generating a non-redundant dataset of nearly 1.3 × 108 amino-oxazole derivatives 
(Figure 2c). This number of molecules is too large for structure-based virtual screening, therefore we 
randomly selected a subset of 8.9 × 106 compounds for subsequent modeling stages (Figure 2d). In 
order to perform molecular docking simulations, for each library molecule, we first generated its  
three-dimensional representation (Figure 2e) and then a non-redundant ensemble of low-energy 
conformations (Figure 2f). Docking simulations were performed against BC structures from seven 
bacterial species (Figure 2g); these structures were constructed by mutating binding site residues in the 
crystal structure of E. coli enzyme according to a multiple sequence alignment of BC isoforms. 
Structure-based virtual screening of amino-oxazole derivatives was carried out using eSimDock [22] 
against all tested BC isoforms (Figure 2h). eSimDock is a pseudo-flexible docking approach, which 
systematically explores all low-energy conformations in the docking ensemble using a rigid-body 
optimization of protein-ligand interactions. In practice, our virtual screening protocol constructed, 
optimized and scored ca. 3.1 × 109 three-dimensional models of drug-target complexes. Subsequently, 
the top-scored conformations selected from individual docking simulations were subjected to all-atom 
refinement using molecular mechanics (Figure 2i). Finally, based on the predicted binding affinity, the 
energy of molecular interactions, and other scores collected from docking and refinement simulations, 
we ranked the library of amino-oxazole derivatives, selected promising inhibitor candidates, and 
performed a detailed analysis of modeled protein-ligand interactions (Figure 2j). 
2.1. Isoforms of Biotin Carboxylase 
Known BC inhibitors, including those based on the amino-oxazole scaffold, target the enzyme’s 
ATP binding site. This region of the BC structure, composed of about 20 amino acid residues listed in 
Table 1, is highly conserved across isoforms from different bacterial species [23]. In order to quantify 
the amino acid variability at a given position in the various BC isoforms we calculated the Shannon 
entropy, which provides a simple measure of uncertainty in a data set [24]. The Shannon entropy was 
determined from sequence profiles generated by PSI-BLAST [25] for E. coli BC against a  
non-redundant collection of protein sequences from the Reference Sequence database (RefSeq) [26]. 
The maximum entropy calculated for a generic protein-like composition according to amino acid 
frequencies provided by UniProtKB/Swiss-Prot [27] is 4.19 bits. The average ± standard deviation 
entropy over the entire BC sequence and binding site residues is only 2.24 ± 0.80 and 1.41 ± 0.76 bits, 
respectively, indicating the residues forming the ATP binding site in BC are indeed highly conserved. 
Nevertheless, some residue positions, e.g., 157, 163, 202, 203, and 438, exhibit noticeable sequence 
variability (residue numbers in this paper are given according to the sequence of E. coli BC). Next, we 
used eFindSite [28] to calculate the probability and confidence of ligand binding for residues within 
the ATP binding site. The primary application of eFindSite is binding pocket prediction, however, it 
can also be used to examine known binding pockets by analyzing ligand-binding patterns across sets of 
closely as well as remotely related proteins. The residues in BC isoforms from Gram-negative and 
Gram-positive species found to be important for ligand binding are listed in Table 1. Several residues, 
e.g., 131, 157, 159, 201-204, 278, and 287-288, are assigned a high ligand-binding probability, which 
shows that these positions often form direct interactions with small molecules in close and remote 
homologues of BC. While many of these are absolutely conserved, e.g., K116, V131, K159,  
Molecules 2014, 19 4027 
 
 
G163-166, E201, Q233, and E276, some positions are consistently different in Gram-negative (M169, 
L204, I287, I437) and Gram-positive species (I169, I204, M287, T437). These subtle sequence 
differences are particularly important in designing broad-spectrum BC inhibitors, which need to 
exhibit a certain level of promiscuity to target the binding sites of BC from both Gram-positive and 
Gram-negative bacteria. 
Table 1. Binding site residues of biotin carboxylase from Gram-negative and Gram-





eFindSite b Sequence, Gram-negative c Sequence, Gram-positive d 
Probability Confidence Ec Hi Pa Mc Ef Sp Sa 
116 0.747 0.687 0.211 K K K K K K K 
131 1.917 0.802 0.452 V V V V V V V 
157 2.003 0.710 0.373 I I I I M I I 
159 0.763 0.733 0.403 K K K K K K K 
163 2.153 0.304 0.159 G G G G G G G 
164 1.289 0.463 0.202 G G G G G G G 
165 0.659 0.553 0.318 G G G G G G G 
166 0.020 0.599 0.355 G G G G G G G 
169 1.861 0.456 0.195 M M M M I I I 
201 1.941 0.870 0.567 E E E E E E E 
202 2.096 0.869 0.419 K K K R K R K 
203 2.183 0.864 0.457 Y Y F F I V F 
204 1.939 0.874 0.660 L L L L I I I 
233 1.130 0.368 0.139 Q Q Q Q Q Q Q 
236 1.924 0.569 0.369 H H H H N N M 
276 0.786 0.553 0.396 E E E E E E E 
278 1.994 0.761 0.608 L L L L L L I 
287 1.137 0.823 0.821 I I I I M M M 
288 0.001 0.755 0.645 E E E E E E E 
437 0.491 0.257 0.174 I I I I T T T 
438 2.586 0.071 0.108 H H H H S S N 
a Calculated from sequence profiles generated by PSI-BLAST. b Probability and confidence of ligand binding 
estimated by eFindSite. c Ec — E. coli, Hi — H. influenzae, Pa — P. aeruginosa, Mc — M. catarrhalis.  
d Ef — E. faecalis, Sp — S. pneumoniae, Sa — S. aureus. 
Three-dimensional models of BC isoforms from H. influenzae, P. aeruginosa, M. catarrhalis, E. 
faecalis, S. pneumoniae, and S. aureus were constructed using homology modeling based on the E. coli 
enzyme. Using the crystal structures of P. aeruginosa (PDB-ID: 2vqd) and S. aureus strains (PDB-ID: 
2vpq), we estimate that the backbone Cα-RMSD of these models is ~1 Å (0.93 Å and 1.02 Å for 2vqd 
and 2vpq, respectively). Furthermore, the heavy-atom RMSD calculated over the ATP binding site in 
the P. aeruginosa and S. aureus BC isoforms is only 1.04 Å and 1.28 Å, respectively. We note that the 
ligand docking approach used in this study, eSimDock, was specifically designed to tolerate structural 
imperfections in modeled protein structures, up to 3–5 Å Cα-RMSD [22], thus the quality of BC 
models is sufficient for their application in structure-based virtual screening. 
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2.2. Molecular Docking Benchmarks  
Ligand docking is a critical component of our virtual screening protocol. It is known that the 
accuracy of docking algorithms depends on the protein target itself as well as its particular 
representation. For example, due to the possible rearrangement of binding site side chains upon ligand 
binding, apo forms as well as structures complexed with different molecules may yield lower docking 
accuracy compared to self-docking [29,30]. Therefore, using BC as a model system, we carried out 
benchmarking calculations for eSimDock [22], which is a new similarity-based docking approach, and 
compared the results to those using AutoDock Vina [31], which is one of the most widely used 
docking programs in computer-aided drug discovery. Structure-based virtual screening is essentially a 
large-scale cross-docking experiment, viz. docking of many compounds to a single ligand-bound target 
structure. Therefore, both algorithms, eSimDock and Vina, are used to dock ATP as well as a series of 
13 known inhibitors to the BC structure from E. coli complexed with ADP (PDB-ID: 2j9g). Table 2 
shows the cross-docking accuracy in terms of ligand heavy-atom RMSD from the corresponding 
crystal structure. Using a threshold of a 2 Å RMSD, Vina and eSimDock correctly reproduced binding 
poses of four and eight compounds, respectively. Furthermore, ATP (PDB-ID: 1dv2) and two other 
compounds based on the quinazoline (PDB-ID: 2w6p) and pyrimidine scaffolds (PDB-ID: 2w71) were 
docked by eSimDock with a relatively low RMSD of 3.035 Å, 2.230 Å and 3.007 Å, respectively. 
Thus, eSimDock provides a higher accuracy than Vina in the modeling of binding poses of known  
BC inhibitors. 
Table 2. Accuracy of binding pose prediction for ATP and BC inhibitors using AutoDock 
Vina and eSimDock. 
PDB-ID a Scaffold AutoDock Vina b eSimDock b 
1dv2 ATP 7.443 3.035 
2v58 pyrido[3,2-d]pyrimidine 2.208 0.992 
2v59 pyrido[3,2-d]pyrimidine 1.372 0.980 
2v5a pyrido[3,2-d]pyrimidine 6.729 1.670 
2w6m 2-amino-oxazole 7.227 0.957 
2w6n 2-amino-oxazole 0.348 4.432 
2w6o 7,8-dihydroquinazoline 7.038 1.331 
2w6p quinazoline 7.127 2.230 
2w6q 1,3,5-triazine 6.591 0.614 
2w6z 3H-purine 5.880 0.317 
2w70 pyrimidine 5.356 1.063 
2w71 pyrimidine 0.481 3.007 
3jzf 1H-benzimidazole 0.721 5.376 
3jzi 1H-benzimidazole 8.515 6.917 
a Cross-docking benchmarks were performed using BC from E. coli complexed with ADP (PDB-ID: 2j9g).  
b Ligand heavy-atom RMSD [Å]. 
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2.3. Library of Amino-Oxazole Derivatives  
Structure-based virtual screening uses molecular docking to rapidly evaluate large compound 
libraries against a given protein target [16,17]. Clearly, the selection of a screening library is pivotal 
for the success of virtual screening simulations. Searching the entire chemical space of organic 
compounds may be unfeasible, thus many virtual screening projects employ targeted compound 
libraries [32,33]. In this study, we focused on a new class of BC inhibitors based on the amino-oxazole 
scaffold. In order to compile a screening library, we first searched the ZINC12 collection of 
commercially available compounds [34] for amino-oxazole derivatives. Three compounds were 
identified: ZINC04368839, ZINC20357591 and ZINC38537247 (shown in Figure 3), whose Tanimoto 
coefficient [35] to amino-oxazole is 0.65, 0.63 and 0.55, respectively. The Tanimoto coefficient is 
widely used in Cheminformatics as a measure of the chemical similarity between organic compounds. 
It is calculated from a comparison of topological fingerprints with typical threshold values of 0.5–0.7 
indicating a significant chemical similarity. Since only three compounds were identified in the ZINC 
database, we used virtual chemistry techniques to construct a large combinatorial library of amino-oxazole 
derivatives. These compounds were assembled by attaching a variety of small organic building blocks 
at positions R1 and R2 of the amino-oxazole scaffold (see Figure 2a). The entire collection comprises 
127,751,751 molecules, ~7% of which were selected for molecular docking to BC isoforms from 
different bacteria species. Figure 4 shows the distribution of various physicochemical properties of the 
amino-oxazole derivatives. The molecular weight of the majority of compounds is within 400–500 Da. 
Typical values for the octanol/water partitioning coefficient and polar surface area are 1–5 and  
100–200 Å2, respectively. Molecules in the library also have 6–12 and 1–4 hydrogen bond acceptors 
and donors, respectively. The vast majority of our screening compounds fit into the criteria known as 
the rule-of-five [36], which means they are likely to be membrane permeable and easily absorbed by 
the body. Furthermore, Figure 4f shows the distribution of internal energy after geometry optimization 
demonstrating that sterically acceptable three-dimensional representations were constructed. 
Figure 3. Compounds identified in the ZINC12 library by fingerprint-based  
virtual screening against 2-amino-oxazole. (a) ZINC04368839, (b) ZINC20357591, and (c) 
ZINC38537247. 
 
2.4. Virtual Screening against Gram-Positive and Gram-Negative Species  
Using similarity-based molecular docking techniques, the combinatorial library of amino-oxazole 
derivatives was subjected to structure-based virtual screening against BC isoforms from seven 
bacterial species including four Gram-negative and three Gram-positive organisms. The amino-oxazole 
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substructure is assumed to adopt a similar conformation when bound to the ATP binding site of BC 
isoforms. This assumption is based on the observation that the amino-oxazole scaffold from two 
different derivatives developed by Pfizer adopts the same conformation when bound to BC from  
E. coli (PDB ID: 2w6m and 2w6n) [12]. Therefore, we selected 1,246,716 compounds whose  
amino-oxazole scaffold was consistently docked within 2 Å RMSD from that in PDB ID: 2w6n across 
all seven BC isoforms. Assuming the independency of individual docking calculations, we estimated 
from the joint probability distribution that the accuracy of ligand docking by eSimDock was 76%, 
which is in accord with docking benchmarks against BC described above as well as with the results of  
large-scale simulations reported previously [22]. 
Figure 4. Distribution of physicochemical properties across a library of amino-oxazole 
derivatives. (a) Molecular weight, (b) octanol/water partitioning coefficient, (c) polar 
surface area, (d) the number of hydrogen bond donors and (e) acceptors, and (f) internal 
energy after geometry optimization in the MMFF94 force field. 
 
To maximize the ranking capabilities of our virtual screening protocol, we used data fusion 
(sometimes called consensus scoring), which was originally developed for applications in signal 
processing [37]. These techniques combine data from different sensors in order to improve the overall 
measurement accuracy in comparison with individual sensors. In the context of virtual screening, 
different sensors correspond to different scoring functions used to rank screening compounds [38,39]. 
Using data fusion, we first combined individual scores, the predicted binding affinity, fitness and 
binding scores, and the total energy of protein-ligand interactions, to rank the compounds for each BC 
isoform. These ranks were then fused into a consensus ranking for all BC isoforms, as well as 
separately against Gram-negative and Gram-positive species. Figure 5 shows the correlation between 
the consensus ranks of amino-oxazole derivatives against BC isoforms from Gram-positive and  
Gram-negative organisms. The Pearson correlation coefficient, which measures the strength of a linear 
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association between two variables, is 0.83 with the regression line slightly shifted towards lower ranks 
for Gram-negative species. It suggests that compound ranking is more consistent across Gram-negative 
organisms, thus Gram-positive BC isoforms create a chemically diverse environment within the ATP 
binding site rendering the development of broad-spectrum inhibitors more difficult. This is in line with 
the pharmacological profiles of known BC inhibitors, which are potent against Gram-negative, but not 
Gram-positive species [12]. 
Figure 5. Log-log plot of the correlation between the ranks of amino-oxazole derivatives 
fused for Gram-positive and Gram-negative species. Each dot represents one compound; its 
relative ranks are expressed as the fraction of the ordered screening library. Thick solid and 
dashed lines are the diagonal and regression line, respectively. Thin dashed lines delineate 
the top 1% and 10% of the ranked library. 
 
2.5. Profiling of ATP Binding Site  
In this study, we focused on BC inhibitors that consist of three distinct parts: a fixed amino-oxazole 
scaffold, and variable substituents R1 and R2. The positions of these substructures within the binding 
pocket of BC are displayed in Figure 6. The amino-oxazole fragment interacts with residues 131, 157, 
159 and 201, which are similar between Gram-negative and Gram-positive species (see Table 1). 
Substituents R1 and R2 interact primarily with residues 169, 203–204, 438, and 233, 276, 278, 287, 
respectively, whereas both moieties interact with residues 233 and 236. Many of these residues are 
chemically similar, e.g., M/I169, I/M287 and L/I204, however, there are some notable differences in 
the chemical properties of some of the amino acids between Gram-negative and Gram-positive BC 
isoforms, e.g., Y/V203, H/N236 and I/T437. 
Molecules 2014, 19 4032 
 
 
Figure 6. ATP binding site of biotin carboxylase from two representative organisms.  
(a) Gram-negative E. coli and (b) Gram-positive S. pneumoniae. Amino-oxazole fragment 
is shown as solid sticks colored by atom type; transparent orange and yellow spheres mark 
the position of two side groups R1 and R2, respectively. Selected binding residues are 
shown as sticks and labeled; purple, orange, yellow and green residues interact primarily 
with the amino-oxazole moiety, side group R1, R2, and both, respectively. 
 
The structures of amino-oxazole derivatives highly ranked against all BC isoforms may give some 
clue on the chemical properties of side groups R1 and R2 required to target both Gram-negative and 
Gram-positive species.  
To that end, we separately clustered, based on chemical similarity, substituents R1 and R2 and 
selected a representative structure from each cluster. Figure 7 shows representative building blocks for 
the ten largest clusters for R1 and R2. Most R1 groups predicted to bind to all BC isoforms comprise 
mono or heterocyclic six-membered aromatic rings as well as fused five-six- and five-five-membered 
aromatic rings. Furthermore, these substructures typically contain two and more halogen atoms. R2 
groups are predominantly composed of smaller aromatic moieties, mono or heterocyclic six- and five-
membered rings, as well as short aliphatic chains. Similar to R1, R2 moieties also often include 
multiple halogen atoms. 
In order to distinguish the similarities and differences between the side groups R1 and R2 with 
respect to Gram-negative and Gram-positive BC isoforms, we partitioned the library of 9,411 building 
blocks into 3,550 clusters using a Tanimoto coefficient threshold of 0.7. For each cluster of similar 
molecules, we calculated the overall enrichment at positions R1 and R2 across the screening library, 
for Gram-negative and Gram-positive species, separately. The BEDROC score was used to quantify 
the enrichment; this acronym stands for Boltzmann-enhanced discrimination of receiver operating 
characteristic [40]. The BEDROC score is a measure of enrichment that effectively accounts for the 
“early recognition problem” when analyzing ordered lists of compounds. The results are presented in 
Figure 8.  
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Figure 7. Representative chemical structures of the top ten clusters of the side groups  
(a) R1 and (b) R2 constructed from the top ranked amino-oxazole derivatives. 
 
Figure 8. Chemical specificity of the side groups R1 (a, c) and R2 (b, d) towards Gram-
positive and Gram-negative species. (a, b) Correlation between BEDROC scores 
calculated using the clusters of building blocks. (c, d) The distribution of BEDROC 
values (residuals) emphasizing the differences between Gram-positive and Gram-negative 
BC isoforms. 
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Figure 8a,b show the correlation of BEDROC scores between Gram-negative and Gram-positive 
BC isoforms at positions R1 and R2, respectively. The Pearson correlation coefficient for R1 and R2 is 
0.91 and 0.93, respectively. Furthermore, Figure 8c,d show the distribution of residuals from the 
correlation plots, defined as the differences between BEDROC scores for Gram-negative and  
Gram-positive species (BEDROC). A higher frequency of BEDROC values below −0.05 and above 
0.05 in Figure 8c compared to Figure 8d demonstrate that more building block clusters at position R1 
are ranked differently using Gram-negative and Gram-positive BC isoforms than those at position R2. 
Consequently, fewer chemical moieties attached at R1 have consistently high ranks against  
Gram-negative and Gram-positive enzymes, suggesting that this position has a potentially higher 
impact on the pharmacological profile of amino-oxazole derivatives. 
2.6. Drug-Target Interactions at the Atomic Level 
A large number of constructed three-dimensional complexes between amino-oxazole derivatives 
and BC isoforms provide a comprehensive dataset to perform a statistical analysis of molecular drug-
target interactions at the atomic level. Using 1,000 top-ranked compounds docked to each enzyme we 
investigated the position and frequency of various intermolecular contacts stabilizing the poses of 
amino-oxazole derivatives within the ATP binding site of BC. These included hydrogen bonds, 
aromatic and hydrophobic interactions as well as destabilizing interactions, defined as hydrophilic-
hydrophobic contacts [41]. Figure 9 shows the frequency and composition of residue-level drug-target 
contacts. The height of each bar corresponds to the fraction of compounds forming interactions with a 
given residue; the relative contribution of these different interactions is shown within individual bars. 
For example, 18%, 28%, 27% and 27% of interactions formed between amino-oxazoles and H236 in 
Gram-negative species are hydrogen bonds, aromatic, hydrophobic and hydrophobic-hydrophilic 
contacts, respectively. In Gram-positive E. faecalis and S. pneumoniae, histidine in this position is 
replaced by asparagine, which interacts with 27%, 36% and 37% of compounds through hydrogen 
bonds, hydrophobic and hydrophobic-hydrophilic contacts, respectively. 
Most binding residues interact with all top-ranked compounds, except for positions 116 and 288, 
which are further away, and thus, form contacts only with a subset of larger compounds, as well as the 
sequence of residues 163–166, which form a glycine-rich loop around the binding site. Most hydrogen 
bonds involve residues K159, E201, K/R202, L/I204, and Q233, which are conserved across all 
species and mainly interact with the amino-oxazole substructure. A number of hydrophobic contacts 
are formed by residues I/M157, M/I169, L/I278, I/M287, and I/T437. BC isoforms from Gram-
negative species form aromatic interactions through residues Y/F203, H236, and H438, whereas 
equivalent residues in Gram-positive organisms form hydrogen bonds and hydrophobic interactions. 
The remaining contacts between hydrophobic and hydrophilic atoms are categorized as destabilizing, 
however, these require further investigation because one of the limitations of the algorithm used to 
classify protein-ligand contacts is that it designates interactions involving halogens as hydrophobic-
hydrophilic. In contrast, halogen contacts in biological systems are commonly considered as weak 
hydrogen bonding interactions [42], thus, about half of the molecules used in drug discovery and 
development are halogenated.  
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Figure 9. Distribution of various types of molecular interactions between the top-ranked 
amino-oxazole derivatives and BC isoforms from different bacteria species. Gram-negative: 
(a) E. coli, (b) H. influenzae, (c) P. aeruginosa, (d) M. catarrhalis; Gram-positive: (e) E. 
faecalis, (f) S. pneumoniae, (g) S. aureus. Four types of non-bonding interactions are 
considered: hydrogen bonds, aromatic and hydrophobic contacts, as well as hydrophilic-
hydrophobic (destabilizing) contacts. Individual graphs correspond to binding residues 
whose numbers in the sequence are shown at the top of each graph. The height of each bar 
shows the fraction of compounds forming interactions with a given binding residue. The 
relative contribution of different interactions is shown within each bar. 
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Since interactions involving halogens as hydrogen bond acceptors play crucial roles in the 
stabilization of protein-ligand complexes [43,44] and a significant number of our top-ranked 
compounds contain halogen atoms, we performed a separate analysis of their interaction patterns 
across BC isoforms. Figure 10 shows that H236 in Gram-negative and N236 in Gram-positive 
organisms frequently form halogen bonds with amino-oxazole derivatives, this residue position is 
favorably positioned to interact with both R1 and R2 side groups. Moreover, a significant number of 
halogen contacts involve two other residues highly conserved across all species, Q233 and E276, 
which primarily interact with the R1 substituent (see Figure 6). These three residues account for the 
majority of halogen interactions between amino-oxazole derivatives and BC enzymes. However, 
depending on the species-specific composition of the binding site, Y203, T437, N438 can also form 
halogen bonds. For instance, in the absence of a halogen bond donor at position 236 in Gram-positive 
S. aureus, halogenated compounds interact with E288, T437 and N438 in addition to Q233 and E276. 
This analysis suggests that the hydrogen bond acceptor capability of halogens can be exploited to 
improve the potency of amino-oxazole derivatives against Gram-positive species.  
Figure 10. Halogen bonding pattern for amino-oxazole derivatives complexed with BC 
isoforms from different bacteria species. (a) Gram-negative, (b) Gram-positive. Individual 
pie charts show the contribution of different binding site residues to halogen bonding with 
the top-ranked compounds. 
 
2.7. Examples of Highly Ranked Compounds  
To conclude this study, we discuss the binding poses of several compounds identified by virtual 
screening as potential broad-spectrum BC inhibitors. But first, in order to fully comprehend why these 
compounds might have broad-spectrum potential, it is necessary to understand the structural basis for 
why the Pfizer compounds only had antibacterial activity against Gram-negative organisms. The left 
panel in Figure 11 shows experimentally determined three-dimensional structures of two amino-oxazole 
derivatives and two other halogenated compounds bound to BC from the Gram-negative E. coli. In the 
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right panel, E. coli residues are mutated according to the sequence of Gram-positive  
S. pneumoniae. Figure 11a,b show a dibenzylamide prototype molecule for a series of amino-oxazole 
derivatives, which has two phenyl moieties at positions R1 and R2. The 2D diagram highlights three 
hydrogen bonds between the amino-oxazole fragment and residues 201, 202 and 204. In the E. coli 
isoform, both R-groups form hydrophobic contacts with residues M169, Y203, H236, L278 and I437. 
Because of the different amino acid composition at these residue positions in S. pneumoniae, the 
phenyl moieties interact only with L278. This difference may be responsible, in part, for the lack of 
potency of this inhibitor against Gram-positive species. The second compound shown in Figure 11c,d 
contains a single side group directly attached to the amino-oxazole scaffold. The bromophenyl moiety 
forms hydrophobic contacts with I437 in E. coli, but the 2D diagram generated using the  
S. pneumoniae isoform shows no direct interactions with binding site residues. The last two complexes 
illustrate binding poses of polyhalogenated inhibitors.  
Figure 11. Binding poses of selected BC inhibitors. (a, b) PDB-ID: 2w6n, (c, d) PDB-ID: 
2w6m, (e, f) PDB-ID: 2w71, and (g, h) PDB-ID: 2v58. BC isoforms from (a, c, e, g)  
E. coli, and (b, d, f, h) S. pneumoniae (E. coli residues are mutated according to  
S. pneumoniae sequence). In 3D representation, selected binding residues are shown as 
orange sticks and labeled. A schematic 2D representation of molecular interactions is 
shown on the right of each 3D binding site; hydrogen bonds and hydrophobic interactions 
are depicted as dashed black and solid green lines, respectively. 
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As shown in Figure 11e–h, dichloro- and dibromophenyl moieties are located in a position close to 
the side group R1 of our prototype inhibitor based on the amino-oxazole scaffold. Both compounds 
form hydrogen bonds with residues 201, 202 and 204, which is a similar pattern as the amino-oxazole 
inhibitors. The compounds also interact with the side chains of Q233, L278 and I437 in the E. coli 
enzyme through their halogenated moieties. Thus, in Gram-positive species substituting isoleucine in 
position 437 with threonine may be responsible for the lower binding affinities of these BC inhibitors. 
This notion is supported by the fact that strains of E. coli that were made resistant to the amino-oxazole 
dibenzylamide (Figure 1b) were found to have a single mutation in which I437 was replaced with 
threonine [12]. 
Five of the top-ranked amino-oxazole derivatives and their putative molecular interactions with BC 
from the Gram-negative E. coli (left panel) and the Gram-positive S. pneumoniae (right panel) are 
shown in Figure 12. In addition, the corresponding docking scores are summarized in Table 3, which 
shows that the amino-oxazole anchors are docked within 2 Å RMSD from that in the crystal structure 
of BC complexed with a known amino-oxazole inhibitor. Fitness and binding probability scores 
reported by eSimDock are close to 1 suggesting that there are no steric clashes and the compounds 
form favorable interactions with the enzymes; this is also supported by the all-atom interaction energy 
calculated using AMMOS. Moreover, the predicted binding affinities are in the nanomolar range. In 
most modeled complexes, binding of the amino-oxazole scaffold is stabilized by multiple hydrogen 
bonds with the side chain carboxylic acid of E201, and the backbone nitrogens of K202 and L204, 
which is consistent with available crystal structures of BC complexed with inhibitors. The first 
compound shown in Figure 12a,b contains both polyhalogenated side groups and interacts with 
residues L278, I437, and L278, M287 in the E. coli and S. pneumoniae enzymes, respectively. 
Interestingly, a larger pyrrolopyridine moiety attached at position R1 reaches deeper into the binding 
site to form a hydrogen bond with H209 in both isoforms. The second compound shown in  
Figure 12c,d revealed a similar interaction with H209 through its pyrazole moiety attached at R1, 
whereas the dihalogenated phenyl substituent at R2 interacted with L278 in BC from both  
Gram-positive and Gram-negative organisms. The compound shown in Figure 12e,f contains a 
halogenated pyrrolopyrimidine moiety at R1, which interacts with the side chain amide of Q233 as 
well as with the hydrophobic side chain of L278; these interactions are present in both BC isoforms. 
Halogenated aromatic substituents of the last two compounds in Figure 12g–j make extensive contacts 
with a hydrophobic pocket formed by residues at positions 157, 169, 171 and 203. These examples 
highlight potential interactions that could be exploited in order to increase the potency of amino-
oxazole inhibitors towards BC enzymes from both Gram-negative as well as Gram-positive species. 
3. Experimental 
3.1. Construction of the Screening Library  
A library of low molecular weight organic building blocks was compiled from the catalogues of the 
following 20 vendors included in the ZINC12 library [45]: ACB Blocks, Accela ChemBio, Angene 
Building Blocks, Aronis BB, Asinex Building Blocks, AsisChem Building Blocks, BePharm Building 
Blocks, ChemDiv BuildingBlocks, ChemBridge BuildingBlocks, Combi-Blocks, EvoBlocks, Life 
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Chemicals BB, Key Organics Building Blocks, Maybridge Building Blocks, Sigma Aldrich Building 
Blocks, SynQuest Building Blocks, Synthonix Building Blocks, Tetrahedron Building Blocks, TimTec 
BB, and Zylexa Pharma BB. We included only fragments that have 6–12 heavy atoms. Removing the 
redundancy at a Tanimoto coefficient [35] threshold of 0.95 using the SUBSET program [46] resulted 
in 9,411 compounds. Next, all combinations of two building blocks that together have up to 18 heavy 
atoms were attached at positions R1 and R2 of the amino-oxazole scaffold shown in Figure 2a. Each 
building block was coupled to the amide nitrogen of amino-oxazole through a hydrogenated carbon, 
nitrogen, oxygen or sulfur atom. All possible combinations were explored, so a pair of two building 
blocks could result in a series of chemically different compounds. Finally, using SUBSET, the 
redundancy was removed at a Tanimoto coefficient of 0.95; the constructed library of amino-oxazole 
derivatives consists of 127,751,751 different molecules. 
Figure 12. Binding poses of selected amino-oxazole derivatives docked to BC. (a, b)  
ao-02168779-40448781-0000, (c, d) ao-00388499-06125795-0000, (e, f) ao-00900729-
40448504-0000, (g, h) ao-02149727-15042121-0000, and (i, j) ao-00403318-01672846-
0002. BC isoforms from (a, c, e, g) E. coli, and (b, d, f, h) S. pneumoniae (E. coli residues 
are mutated according to S. pneumoniae sequence). In 3D representation, selected binding 
residues are shown as orange sticks and labeled. A schematic 2D representation of 
molecular interactions is shown on the right of each 3D binding site; hydrogen bonds and 
hydrophobic interactions are depicted as dashed black and solid green lines, respectively. 
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Table 3. Examples of top ranked amino-oxazole derivatives selected by virtual screening 
against BC and their docking scores. 
Compound ID a 
ao-RMSD b [Å] Fitness c Binding d Affinity e Energy f [kcal/mol] 
Ec g Sp g Ec Sp Ec Sp Ec Sp Ec Sp 
ao-02168779-40448781-000 1.41 1.42 1.00 1.00 1.00 1.00 0.71 0.79 38.19 50.52 
ao-00388499-06125795-000 1.79 1.84 1.00 1.00 1.00 0.91 0.36 -0.05 40.68 4.30 
ao-00900729-40448504-000 1.93 1.92 1.00 1.00 0.99 0.96 −0.12 0.55 37.96 20.95 
ao-02149727-15042121-000 1.81 1.82 1.00 1.00 1.00 0.99 0.22 0.57 84.23 32.37 
ao-00403318-01672846-002 1.83 1.83 1.00 1.00 1.00 0.99 −0.45 0.39 89.74 34.06 
a the first field is a code for amino-oxazole, the second and third fields are the ZINC-ID of R1 and R2, respectively, the 
last field is a combination number. b All-atom RMSD calculated over the amino-oxazole fragment vs. 2w6n. c Fitness and 
d binding scores reported by eSimDock. e Binding affinity predicted by eSimDock, expressed as ln Ki.
 f Interaction energy 
reported by AMMOS. g Ec — E. coli, Sp — S. pneumoniae. 
3.2. Generation of 3D Conformations and Conformational Ensembles 
We used Open Babel [47] to generate three-dimensional molecular structures for a subset of 10  106 
compounds randomly selected from the library of amino-oxazole derivatives, followed by geometry 
optimization in the Merck MMFF94 force field [48]. This procedure resulted in 8,898,942 “clean” 
chemical structures without atomic clashes and having acceptable bond lengths and angles. 
Subsequently, for each compound, we generated a large ensemble of low-energy conformations using 
Balloon and the MMFF94-like force field [49]. An initial ensemble was subject to the clustering 
procedure using CLUTO [50] and a pairwise similarity threshold of 1 Å RMSD for the atomic 
coordinates. Depending on the number of rotatable bonds, the final non-redundant ensemble contains 
up to 50 different low-energy structures. 
3.3. BC Isoform Structures  
The crystal structure of BC from Escherichia coli (PDB-ID: 2j9g) was used to model BC isoforms 
from the following bacteria species: (Gram-negative) Haemophilus influenzae, Pseudomonas 
aeruginosa, Moraxella catarrhalis, (Gram-positive) Enterococcus faecalis, Streptococcus pneumoniae, 
and Staphylococcus aureus. Side chains of binding site residues were mutated to those from a different 
species according to multiple sequence alignments reported previously [23] and the resulting structures 
were subjected to energy minimization. Both residue mutation and energy optimization was carried out 
using the Jackal modeling package [51]. The assignment of partial charges to target protein structures 
as well as the conversion to the PDBQT format were done using MGL Tools [52]. 
3.4. Similarity-Based Ligand Docking and Pose Refinement 
Amino-oxazole derivatives were docked to all seven BC isoforms using the recently developed 
eSimDock [22]. The ability of eSimDock to predict ligand binding poses and the corresponding 
affinities was previously benchmarked on a large dataset of 1,151 complexes selected from  
BindingDB [53] using crystal structures as well as the modeled conformations of target proteins [22]. 
Furthermore, these benchmarking simulations included two case studies on the inhibitors of fXa and 
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CDK2, which are computationally similar to docking of amino-oxazole derivatives to BC isoforms. 
Using eSimDock gave equally encouraging results in both cases, therefore we selected this  
approach for the current study focusing on BC inhibitors. As the anchor, we used the conformation  
of amino-oxazole substructure from the crystal structure of BC complexed with 2-amino-N,N-
bis(phenylmethyl)-1,3-oxazole-5-carboxamide (PDB-ID: 2w6n). eSimDock performs a rigid-body 
superposition of each conformation from the docking ensemble onto the anchor substructure and 
optimizes the orientation of flexible regions (in our case the side groups R1 and R2) within the binding 
site of the target structure. Next, the best binding pose was selected using non-linear machine learning 
models; the final docking result was also assigned a binding score and binding affinity. In addition, 
ligand poses modeled by eSimDock were refined by molecular mechanics using AMMOS [54] and the 
standard AMMP force field sp5 [55]. 
3.5. Ligand Scoring and Ranking  
For each amino-oxazole derivative docked into each BC isoform, we calculated the heavy-atom 
RMSD from the amino-oxazole anchor substructure (PDB-ID: 2w6n). Next, we selected only those 
conformations whose RMSD is ≤2 Å across all BC complexes; this procedure resulted in 1,246,716 
compounds. Ligand ranking was performed using data fusion with the SUM rule [37,56] and the 
following 4 docking scores: (from eSimDock) predicted binding affinity, predicted fitness and binding 
scores, (from AMMOS) the total energy of protein-ligand interactions. Three rank-ordered lists of 
compounds were constructed separately for Gram-negative and Gram-positive organisms, as well as 
for all species. 
3.6. Analysis of Drug-Target Interactions  
Our primary tool for analyzing protein-ligand interaction is LPC (Ligand-Protein Contacts), which 
detects and classifies interatomic contacts based on the solvent-accessible surface calculations and 
evaluates the interface complementarity [41]. In addition, binding poses of amino-oxazole derivatives 
in BC pockets were visualized in 3D using VMD (Visual Molecular Dynamics) [57] and flattened to 
2D complex diagrams by PoseView [58]. 
4. Conclusions 
In an effort to improve the pharmacological profile of biotin carboxylase inhibitors, we performed 
virtual screening of a diverse combinatorial library of amino-oxazoles against isoforms from several 
Gram-negative and Gram-positive bacteria species. The amino-oxazole scaffold was selected primarily 
because of its high synthetic tractability, viz. the carboxyl group on amino-oxazole can be easily 
coupled to fragments containing a nucleophilic nitrogen using standard peptide chemistry to generate 
novel series of compounds. Structure-based virtual screening was conducted using eSimDock, a new 
similarity-based docking approach. Under the assumption that the amino-oxazole substructure adopts a 
similar conformation when complexed with different BC isoforms, the accuracy of ligand docking by 
eSimDock is 76%. By analyzing compound ranking, we find that the development of broad-spectrum 
inhibitors is challenging because the ATP binding site of BC creates a chemically diverse environment, 
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particularly across Gram-positive species. Amino-oxazole derivatives contain two side groups, R1 and 
R2. Most R1 groups in inhibitors selected by virtual screening comprise either mono or heterocyclic, 
six-membered or fused aromatic rings, whereas smaller aromatic moieties and short aliphatic chains 
are attached at R2. Moreover, both the R1 and R2 side groups are frequently halogenated. Comparing 
side groups R1 and R2 across Gram-negative and Gram-positive BC isoforms indicates that R1 may 
have a potentially higher impact on the pharmacological profile of amino-oxazole derivatives. The 
analysis of binding poses of the top-ranked compounds suggests that (1) binding of the amino-oxazole 
anchor is stabilized by a network of hydrogen bonds to residues 201, 202 and 204; (2) halogenated 
aromatic moieties enhance interactions with a hydrophobic pocket formed by residues 157, 169, 171 
and 203; and (3) larger moieties attached at R1 reach deeper into the binding pocket to form hydrogen 
bonds with the side chains of conserved residues 209 and 233. These insights obtained from the 
present in silico study will be next tested experimentally in both in vitro and in vivo systems. 
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